Zollinger‑Ellison disease (type I) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Disease (Type I) – Complete Medical Guide

Zollinger‑Ellison Disease (Type I) – A Comprehensive Patient Guide

Overview

Zollinger‑Ellison disease (ZED), also called a gastrinoma, is a rare disorder in which one or more tumors (gastrin‑secreting neuroendocrine tumors) arise in the pancreas or duodenum. These tumors produce excess gastrin, a hormone that stimulates the stomach lining to secrete large amounts of gastric acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and malabsorption.

  • Prevalence: Approximately 1–3 cases per million people worldwide, accounting for < 0.1 % of all peptic‑ulcer disease.1
  • Age: Most patients are diagnosed between 30 and 60 years, though it can occur at any age.
  • Gender: Slight male predominance (≈ 55 % male).2
  • Type I vs. Type II: Type I is sporadic (no inherited mutation); Type II occurs in patients with Multiple Endocrine Neoplasia type 1 (MEN‑1). This guide focuses on Type I.

Symptoms

Symptoms stem from excess acid and from the tumor’s size or location. Not every patient will have all of these, but most experience a combination.

Gastro‑intestinal symptoms

  • Refractory peptic ulcer disease: Ulcers that recur despite standard therapy, often multiple and located in atypical sites (duodenum past the bulb, jejunum, or even the esophagus).
  • Severe epigastric pain: Burning or gnawing pain that may improve with meals (ulcer pain) or worsen (acid reflux).
  • Heartburn & gastro‑esophageal reflux disease (GERD): Due to overwhelming acid load.
  • Chronic diarrhea: Stools are watery, sometimes greasy, resulting from acid‑induced damage to the intestinal mucosa and bile‑salt malabsorption.
  • Nausea & vomiting: May be intermittent or persistent, especially after large meals.

Systemic symptoms

  • Weight loss: From malabsorption, chronic diarrhea, and decreased appetite.
  • Fatigue & anemia: Chronic blood loss from ulcerations can cause iron‑deficiency anemia.
  • Facial flushing or sweating: Rare, associated with larger tumors releasing other neuroendocrine hormones.

Symptoms related to tumor size/location

  • Abdominal mass or fullness: Large gastrinomas (> 2 cm) may be palpable.
  • Pain radiating to the back: Typical of pancreatic lesions.

Causes and Risk Factors

Zollinger‑Ellison disease type I is considered sporadic, meaning there is no known hereditary mutation. The exact trigger for gastrinoma formation is unclear, but several factors have been identified.

Primary cause

  • Neoplastic transformation of neuroendocrine cells in the pancreas or duodenum leading to autonomous gastrin production.

Risk factors

  • Age & gender: Middle‑aged adults, slightly more common in men.
  • Family history of neuroendocrine tumors: While type I is not inherited, a family history may increase vigilance.
  • Chronic gastritis or H. pylori infection: May mask or exacerbate ulcer symptoms, delaying diagnosis.
  • Smoking: Associated with many neuroendocrine tumors, though data specific to ZED are limited.

Diagnosis

Because the condition is rare and its symptoms overlap with common ulcer disease, a high index of suspicion is needed.

Step‑by‑step diagnostic work‑up

  1. Clinical assessment: Detailed history of refractory ulcers, diarrhea, and weight loss.
  2. Laboratory testing:
    • Fasting serum gastrin level: Values > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when the gastric pH is low (< 2).3
    • Secretin stimulation test: Gastrin levels rise > 120 pg/mL after IV secretin in > 80 % of patients with ZED.
    • Chromogranin A: General neuroendocrine tumor marker; elevated in > 70 % of cases.
    • Complete blood count, iron studies, and stool tests for occult blood.
  3. Imaging studies to locate the tumor:
    • Endoscopic ultrasound (EUS): Highly sensitive for tumors < 1 cm in pancreas or duodenum.
    • Multiphasic contrast‑enhanced CT or MRI of the abdomen: Detects larger lesions and assesses liver metastases.
    • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Gold standard for neuroendocrine tumor localization and staging.
  4. Endoscopy: Upper GI endoscopy visualizes ulcer burden; biopsies are taken to exclude Helicobacter pylori and rule out malignancy unrelated to gastrinoma.

Diagnostic criteria (simplified)

  • Fasting gastrin > 1,000 pg/mL with gastric pH < 2, or
  • Fasting gastrin > 150 pg/mL with a positive secretin stimulation test, plus imaging evidence of a gastrinoma.

Treatment Options

Management combines acid suppression, tumor control, and symptom relief.

1. Acid‑blocking medications (first line)

  • Proton‑pump inhibitors (PPIs): Omeprazole, esomeprazole, pantoprazole, or lansoprazole at high doses (e.g., omeprazole 60‑80 mg/day) are required in 80‑90 % of patients to control acid hypersecretion.4
  • H2‑receptor antagonists: May be added if PPIs alone are insufficient, but they are less effective for the extreme gastrin‑driven acid load.
  • Patients typically need lifelong therapy; dose titration is guided by symptom control and ulcer healing on repeat endoscopy.

2. Surgical removal of the gastrinoma

  • Goal: cure or debulk the tumor, reduce gastrin levels, and prevent metastasis.
  • Procedures:
    • Enucleation: For small (< 2 cm), well‑localized tumors without invasion.
    • Pancreaticoduodenectomy (Whipple) or distal pancreatectomy: For larger or anatomically complex lesions.
  • Curative resection is possible in ~ 60‑70 % of sporadic Type I cases when disease is localized.

3. Medical therapy for unresectable or metastatic disease

  • Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and can shrink tumor size.
  • Targeted therapy (everolimus, sunitinib): Approved for progressive, well‑differentiated pancreatic neuroendocrine tumors.
  • Chemotherapy: Reserved for high‑grade or rapidly progressive disease; regimens include streptozocin‑based combinations.
  • Liver‑directed therapies: Radiofrequency ablation or transarterial embolization for hepatic metastases.

4. Lifestyle & supportive measures

  • Small, frequent meals; avoid large fatty meals that stimulate acid.
  • Limit caffeine, alcohol, chocolate, and spicy foods which can aggravate reflux.
  • Stay hydrated; oral rehydration solutions help replace electrolytes lost in diarrhea.
  • Supplement iron, vitamin B12, and fat‑soluble vitamins (A, D, E, K) if malabsorption is documented.

Living with Zollinger‑Ellison Disease (Type I)

Long‑term management focuses on controlling acid, monitoring tumor status, and maintaining nutrition.

Daily management checklist

  1. Take PPIs exactly as prescribed. Do not skip doses.
  2. Track symptoms: Keep a log of pain, heartburn, stool frequency, and weight.
  3. Nutrition: Aim for 5–6 small meals, incorporate protein‑rich foods, and consider a dietitian referral.
  4. Hydration: Drink ≥ 2 L of water daily; oral rehydration salts if diarrhea is frequent.
  5. Medication review: Inform every physician about your condition; PPIs can interact with certain antifungals and antiretrovirals.
  6. Regular follow‑up:
    • Endoscopy every 1–2 years to assess ulcer healing.
    • Serum gastrin and chromogranin A levels every 6–12 months.
    • Imaging (CT/MRI or Ga‑68 PET) annually or sooner if symptoms change.
  7. Vaccinations: If you’re on immunosuppressive therapy (e.g., everolimus), stay up to date with flu, COVID‑19, and pneumococcal vaccines.

Psychosocial aspects

  • Living with a rare disease can be stressful. Seek support groups (e.g., North American Neuroendocrine Tumor Society).
  • Consider counseling if anxiety about ulcer recurrence or cancer spread interferes with daily life.

Prevention

Because Type I ZED is sporadic and not linked to modifiable lifestyle factors, primary prevention is limited. However, certain actions can help reduce the impact or detect disease earlier.

  • Prompt evaluation of persistent ulcer symptoms: If ulcers recur despite standard therapy, request gastrin testing.
  • Manage H. pylori infection: Eradication reduces background ulcer risk and may lessen diagnostic delay.
  • Avoid excessive NSAID use: Non‑steroidal anti‑inflammatory drugs can worsen ulcer disease.
  • Smoking cessation: Lowers overall gastrointestinal cancer risk.

Complications

If untreated or poorly controlled, ZED can lead to serious health problems.

  • Perforated peptic ulcer: Acute abdominal emergency with risk of peritonitis.
  • Bleeding ulcer: Can cause melena, hematemesis, and severe anemia.
  • Duodenal or jejunal strictures: From chronic ulcer scarring, leading to obstruction.
  • Metastatic disease: Approximately 20‑30 % of sporadic gastrinomas develop liver or lymph‑node metastases over time.5
  • Malnutrition & electrolyte disturbances: Chronic diarrhea may cause hypokalemia, metabolic alkalosis, and vitamin deficiencies.
  • Increased risk of gastric cancer: Persistent acid hypersecretion can promote dysplasia; surveillance endoscopy is advised.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red or “coffee‑ground” appearance) or passing black, tarry stools.
  • Signs of perforation: sudden onset of sharp abdominal pain with a rigid, board‑like abdomen.
  • Fainting, rapid heartbeat, or a drop in blood pressure (possible severe bleeding).
  • Persistent vomiting that prevents you from keeping fluids down for more than 24 hours.

These symptoms may indicate a bleeding ulcer, perforation, or severe electrolyte imbalance and require immediate medical attention.

References

  1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
  2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2022.
  3. American College of Gastroenterology. “Guidelines for the Diagnosis and Management of Gastric Neuroendocrine Tumors.” Gastroenterology, 2021.
  4. Cleveland Clinic. “Proton Pump Inhibitors: Uses and Side Effects.” 2024.
  5. Yao JC, et al. “One Hundred Years of Neuroendocrine Tumors.” J Clin Oncol, 2020;38(12):1369‑1379.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References